Karolina Nemes Selected Research

Neoplasms (Cancer)

4/2022	The need for tumor surveillance of children and adolescents with cancer predisposition syndromes: a retrospective cohort study in a tertiary-care children's hospital.
1/2021	Inhibition of nuclear export restores nuclear localization and residual tumor suppressor function of truncated SMARCB1/INI1 protein in a molecular subset of atypical teratoid/rhabdoid tumors.
1/2021	Atypical Teratoid/Rhabdoid Tumor (AT/RT) With Molecular Features of Pleomorphic Xanthoastrocytoma.
1/2021	Histopathological patterns in atypical teratoid/rhabdoid tumors are related to molecular subgroup.
1/2020	Age and DNA methylation subgroup as potential independent risk factors for treatment stratification in children with atypical teratoid/rhabdoid tumors.
1/2018	Germline variants in SMARCB1 and other members of the BAF chromatin-remodeling complex across human disease entities: a meta-analysis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Karolina Nemes Research Topics

Disease

6	Neoplasms (Cancer) 04/2022 - 01/2018
5	Rhabdoid Tumor (Rhabdoid Tumors) 12/2021 - 01/2018
2	Typical Teratoid Rhabdoid Tumor 01/2022 - 01/2021
2	Leukemia 07/2015 - 01/2013
2	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 07/2015 - 01/2013
2	Lymphoma (Lymphomas) 07/2015 - 12/2012
1	Central Nervous System Neoplasms 01/2022
1	Li-Fraumeni Syndrome 01/2022
1	Glioma (Gliomas) 01/2022
1	Hematologic Neoplasms (Hematological Malignancy) 12/2021
1	Rhabdoid Tumor Predisposition Syndrome 1 01/2021
1	Residual Neoplasm 01/2021
1	Coffin-Siris syndrome 01/2018
1	Nicolaides Baraitser syndrome 01/2018
1	Non-Hodgkin Lymphoma (Lymphosarcoma) 12/2012
1	B-Cell Lymphoma (Lymphoma, B Cell) 12/2012
1	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 12/2012
1	Mantle-Cell Lymphoma (Lymphoma, Mantle Cell) 12/2012
1	Osteosarcoma (Osteogenic Sarcoma) 10/2012

Drug/Important Bio-Agent (IBA)

7	Proteins (Proteins, Gene)FDA Link 01/2022 - 12/2012
3	NucleotidesIBA 01/2021 - 01/2018
1	CPS 49IBA 04/2022
1	Biological ProductsIBA 12/2021
1	Decitabine FDA Link 12/2021
1	selinexorIBA 01/2021
1	SMARCB1 ProteinIBA 01/2021
1	DNA Transposable Elements (Element, IS)IBA 01/2021
1	Eosine Yellowish-(YS) (Eosin)IBA 01/2021
1	Hematoxylin (Haematoxylon)IBA 01/2021
1	Cyclin D1IBA 01/2018
1	CateninsIBA 01/2018
1	Aurora Kinase AIBA 01/2018
1	Prednisolone (Predate)FDA LinkGeneric 07/2015
1	MicroRNAs (MicroRNA)IBA 07/2015
1	Ribosomal Proteins (Ribosomal Protein)IBA 01/2013
1	TOR Serine-Threonine KinasesIBA 01/2013
1	Eukaryotic Initiation Factor-4EIBA 01/2013
1	Carrier Proteins (Binding Protein)IBA 01/2013
1	PhosphoproteinsIBA 12/2012
1	MTOR InhibitorsIBA 12/2012
1	Leucovorin (Folinic Acid)FDA Link 10/2012
1	Methotrexate (Mexate)FDA LinkGeneric 10/2012

Therapy/Procedure

4	Therapeutics 12/2021 - 12/2012
2	Radiotherapy 11/2020 - 01/2020
1	Immunotherapy 01/2018